Review





Similar Products

decitabine  (MedChemExpress)
96
MedChemExpress decitabine
A Reactome enrichment analysis of changed pathways in SLC46A1-downregulated HCT8 cells. B Heatmap of the altered genes in HCT8 cells inhibiting SLC46A1 compared with negative controls. C , D FOS mRNA and protein levels after shSLC46A1 transfection in DiFi and HCT8 cells. E , F FOS mRNA and protein levels in SLC46A1-inhibited cells treated with folate or PBS. G Global 5-mC levels in SLC46A1-downregulated DiFi and HCT8 cells. H Global 5-mC levels in DiFi and HCT8 cells treated with folate or PBS. I FOS mRNA levels in DiFi and HCT8 cells treated with folate and DAC or DMSO. J CpG island prediction in the FOS promoter region using MethPrimer; changes in FOS promoter DNA methylation (left) and quantitative analysis of CpG methylation within Area 1 of the FOS promoter after SLC46A1 knockdown (right). Bar plot data are expressed as the mean ± SD. Significant differences were assessed by one-way ANOVA ( C , I ) or Student’s t tests ( E , G , H , J right). * p < 0.05, ** p < 0.01, *** p < 0.001. <t>Decitabine</t> (DAC), Enzyme-linked immunosorbent assay (ELISA), 5-methylcytosine (5-mC), next-generation sequencing bisulfite pyrosequencing (NGS-BSP).
Decitabine, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/decitabine/product/MedChemExpress
Average 96 stars, based on 1 article reviews
decitabine - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier
hy a0004r  (MedChemExpress)
96
MedChemExpress hy a0004r
A Reactome enrichment analysis of changed pathways in SLC46A1-downregulated HCT8 cells. B Heatmap of the altered genes in HCT8 cells inhibiting SLC46A1 compared with negative controls. C , D FOS mRNA and protein levels after shSLC46A1 transfection in DiFi and HCT8 cells. E , F FOS mRNA and protein levels in SLC46A1-inhibited cells treated with folate or PBS. G Global 5-mC levels in SLC46A1-downregulated DiFi and HCT8 cells. H Global 5-mC levels in DiFi and HCT8 cells treated with folate or PBS. I FOS mRNA levels in DiFi and HCT8 cells treated with folate and DAC or DMSO. J CpG island prediction in the FOS promoter region using MethPrimer; changes in FOS promoter DNA methylation (left) and quantitative analysis of CpG methylation within Area 1 of the FOS promoter after SLC46A1 knockdown (right). Bar plot data are expressed as the mean ± SD. Significant differences were assessed by one-way ANOVA ( C , I ) or Student’s t tests ( E , G , H , J right). * p < 0.05, ** p < 0.01, *** p < 0.001. <t>Decitabine</t> (DAC), Enzyme-linked immunosorbent assay (ELISA), 5-methylcytosine (5-mC), next-generation sequencing bisulfite pyrosequencing (NGS-BSP).
Hy A0004r, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hy a0004r/product/MedChemExpress
Average 96 stars, based on 1 article reviews
hy a0004r - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier
hy a0004  (MedChemExpress)
96
MedChemExpress hy a0004
A Reactome enrichment analysis of changed pathways in SLC46A1-downregulated HCT8 cells. B Heatmap of the altered genes in HCT8 cells inhibiting SLC46A1 compared with negative controls. C , D FOS mRNA and protein levels after shSLC46A1 transfection in DiFi and HCT8 cells. E , F FOS mRNA and protein levels in SLC46A1-inhibited cells treated with folate or PBS. G Global 5-mC levels in SLC46A1-downregulated DiFi and HCT8 cells. H Global 5-mC levels in DiFi and HCT8 cells treated with folate or PBS. I FOS mRNA levels in DiFi and HCT8 cells treated with folate and DAC or DMSO. J CpG island prediction in the FOS promoter region using MethPrimer; changes in FOS promoter DNA methylation (left) and quantitative analysis of CpG methylation within Area 1 of the FOS promoter after SLC46A1 knockdown (right). Bar plot data are expressed as the mean ± SD. Significant differences were assessed by one-way ANOVA ( C , I ) or Student’s t tests ( E , G , H , J right). * p < 0.05, ** p < 0.01, *** p < 0.001. <t>Decitabine</t> (DAC), Enzyme-linked immunosorbent assay (ELISA), 5-methylcytosine (5-mC), next-generation sequencing bisulfite pyrosequencing (NGS-BSP).
Hy A0004, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hy a0004/product/MedChemExpress
Average 96 stars, based on 1 article reviews
hy a0004 - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier
aza cdr dac  (MedChemExpress)
96
MedChemExpress aza cdr dac
A Reactome enrichment analysis of changed pathways in SLC46A1-downregulated HCT8 cells. B Heatmap of the altered genes in HCT8 cells inhibiting SLC46A1 compared with negative controls. C , D FOS mRNA and protein levels after shSLC46A1 transfection in DiFi and HCT8 cells. E , F FOS mRNA and protein levels in SLC46A1-inhibited cells treated with folate or PBS. G Global 5-mC levels in SLC46A1-downregulated DiFi and HCT8 cells. H Global 5-mC levels in DiFi and HCT8 cells treated with folate or PBS. I FOS mRNA levels in DiFi and HCT8 cells treated with folate and DAC or DMSO. J CpG island prediction in the FOS promoter region using MethPrimer; changes in FOS promoter DNA methylation (left) and quantitative analysis of CpG methylation within Area 1 of the FOS promoter after SLC46A1 knockdown (right). Bar plot data are expressed as the mean ± SD. Significant differences were assessed by one-way ANOVA ( C , I ) or Student’s t tests ( E , G , H , J right). * p < 0.05, ** p < 0.01, *** p < 0.001. <t>Decitabine</t> (DAC), Enzyme-linked immunosorbent assay (ELISA), 5-methylcytosine (5-mC), next-generation sequencing bisulfite pyrosequencing (NGS-BSP).
Aza Cdr Dac, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/aza cdr dac/product/MedChemExpress
Average 96 stars, based on 1 article reviews
aza cdr dac - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier
5 aza cdr dac  (MedChemExpress)
96
MedChemExpress 5 aza cdr dac
A Reactome enrichment analysis of changed pathways in SLC46A1-downregulated HCT8 cells. B Heatmap of the altered genes in HCT8 cells inhibiting SLC46A1 compared with negative controls. C , D FOS mRNA and protein levels after shSLC46A1 transfection in DiFi and HCT8 cells. E , F FOS mRNA and protein levels in SLC46A1-inhibited cells treated with folate or PBS. G Global 5-mC levels in SLC46A1-downregulated DiFi and HCT8 cells. H Global 5-mC levels in DiFi and HCT8 cells treated with folate or PBS. I FOS mRNA levels in DiFi and HCT8 cells treated with folate and DAC or DMSO. J CpG island prediction in the FOS promoter region using MethPrimer; changes in FOS promoter DNA methylation (left) and quantitative analysis of CpG methylation within Area 1 of the FOS promoter after SLC46A1 knockdown (right). Bar plot data are expressed as the mean ± SD. Significant differences were assessed by one-way ANOVA ( C , I ) or Student’s t tests ( E , G , H , J right). * p < 0.05, ** p < 0.01, *** p < 0.001. <t>Decitabine</t> (DAC), Enzyme-linked immunosorbent assay (ELISA), 5-methylcytosine (5-mC), next-generation sequencing bisulfite pyrosequencing (NGS-BSP).
5 Aza Cdr Dac, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/5 aza cdr dac/product/MedChemExpress
Average 96 stars, based on 1 article reviews
5 aza cdr dac - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier
5 aza cdr  (MedChemExpress)
96
MedChemExpress 5 aza cdr
A Reactome enrichment analysis of changed pathways in SLC46A1-downregulated HCT8 cells. B Heatmap of the altered genes in HCT8 cells inhibiting SLC46A1 compared with negative controls. C , D FOS mRNA and protein levels after shSLC46A1 transfection in DiFi and HCT8 cells. E , F FOS mRNA and protein levels in SLC46A1-inhibited cells treated with folate or PBS. G Global 5-mC levels in SLC46A1-downregulated DiFi and HCT8 cells. H Global 5-mC levels in DiFi and HCT8 cells treated with folate or PBS. I FOS mRNA levels in DiFi and HCT8 cells treated with folate and DAC or DMSO. J CpG island prediction in the FOS promoter region using MethPrimer; changes in FOS promoter DNA methylation (left) and quantitative analysis of CpG methylation within Area 1 of the FOS promoter after SLC46A1 knockdown (right). Bar plot data are expressed as the mean ± SD. Significant differences were assessed by one-way ANOVA ( C , I ) or Student’s t tests ( E , G , H , J right). * p < 0.05, ** p < 0.01, *** p < 0.001. <t>Decitabine</t> (DAC), Enzyme-linked immunosorbent assay (ELISA), 5-methylcytosine (5-mC), next-generation sequencing bisulfite pyrosequencing (NGS-BSP).
5 Aza Cdr, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/5 aza cdr/product/MedChemExpress
Average 96 stars, based on 1 article reviews
5 aza cdr - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier
ladakamycin medchemexpress hy 10586r decitabine medchemexpress hy a0004r arsenic trioxide sigma aldrich  (MedChemExpress)
96
MedChemExpress ladakamycin medchemexpress hy 10586r decitabine medchemexpress hy a0004r arsenic trioxide sigma aldrich
A Reactome enrichment analysis of changed pathways in SLC46A1-downregulated HCT8 cells. B Heatmap of the altered genes in HCT8 cells inhibiting SLC46A1 compared with negative controls. C , D FOS mRNA and protein levels after shSLC46A1 transfection in DiFi and HCT8 cells. E , F FOS mRNA and protein levels in SLC46A1-inhibited cells treated with folate or PBS. G Global 5-mC levels in SLC46A1-downregulated DiFi and HCT8 cells. H Global 5-mC levels in DiFi and HCT8 cells treated with folate or PBS. I FOS mRNA levels in DiFi and HCT8 cells treated with folate and DAC or DMSO. J CpG island prediction in the FOS promoter region using MethPrimer; changes in FOS promoter DNA methylation (left) and quantitative analysis of CpG methylation within Area 1 of the FOS promoter after SLC46A1 knockdown (right). Bar plot data are expressed as the mean ± SD. Significant differences were assessed by one-way ANOVA ( C , I ) or Student’s t tests ( E , G , H , J right). * p < 0.05, ** p < 0.01, *** p < 0.001. <t>Decitabine</t> (DAC), Enzyme-linked immunosorbent assay (ELISA), 5-methylcytosine (5-mC), next-generation sequencing bisulfite pyrosequencing (NGS-BSP).
Ladakamycin Medchemexpress Hy 10586r Decitabine Medchemexpress Hy A0004r Arsenic Trioxide Sigma Aldrich, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ladakamycin medchemexpress hy 10586r decitabine medchemexpress hy a0004r arsenic trioxide sigma aldrich/product/MedChemExpress
Average 96 stars, based on 1 article reviews
ladakamycin medchemexpress hy 10586r decitabine medchemexpress hy a0004r arsenic trioxide sigma aldrich - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier

Image Search Results


A Reactome enrichment analysis of changed pathways in SLC46A1-downregulated HCT8 cells. B Heatmap of the altered genes in HCT8 cells inhibiting SLC46A1 compared with negative controls. C , D FOS mRNA and protein levels after shSLC46A1 transfection in DiFi and HCT8 cells. E , F FOS mRNA and protein levels in SLC46A1-inhibited cells treated with folate or PBS. G Global 5-mC levels in SLC46A1-downregulated DiFi and HCT8 cells. H Global 5-mC levels in DiFi and HCT8 cells treated with folate or PBS. I FOS mRNA levels in DiFi and HCT8 cells treated with folate and DAC or DMSO. J CpG island prediction in the FOS promoter region using MethPrimer; changes in FOS promoter DNA methylation (left) and quantitative analysis of CpG methylation within Area 1 of the FOS promoter after SLC46A1 knockdown (right). Bar plot data are expressed as the mean ± SD. Significant differences were assessed by one-way ANOVA ( C , I ) or Student’s t tests ( E , G , H , J right). * p < 0.05, ** p < 0.01, *** p < 0.001. Decitabine (DAC), Enzyme-linked immunosorbent assay (ELISA), 5-methylcytosine (5-mC), next-generation sequencing bisulfite pyrosequencing (NGS-BSP).

Journal: Cell Death & Disease

Article Title: SLC46A1 deficiency-mediated folate restriction suppresses colorectal cancer progression through epigenetic-transcriptional reprogramming

doi: 10.1038/s41419-026-08423-8

Figure Lengend Snippet: A Reactome enrichment analysis of changed pathways in SLC46A1-downregulated HCT8 cells. B Heatmap of the altered genes in HCT8 cells inhibiting SLC46A1 compared with negative controls. C , D FOS mRNA and protein levels after shSLC46A1 transfection in DiFi and HCT8 cells. E , F FOS mRNA and protein levels in SLC46A1-inhibited cells treated with folate or PBS. G Global 5-mC levels in SLC46A1-downregulated DiFi and HCT8 cells. H Global 5-mC levels in DiFi and HCT8 cells treated with folate or PBS. I FOS mRNA levels in DiFi and HCT8 cells treated with folate and DAC or DMSO. J CpG island prediction in the FOS promoter region using MethPrimer; changes in FOS promoter DNA methylation (left) and quantitative analysis of CpG methylation within Area 1 of the FOS promoter after SLC46A1 knockdown (right). Bar plot data are expressed as the mean ± SD. Significant differences were assessed by one-way ANOVA ( C , I ) or Student’s t tests ( E , G , H , J right). * p < 0.05, ** p < 0.01, *** p < 0.001. Decitabine (DAC), Enzyme-linked immunosorbent assay (ELISA), 5-methylcytosine (5-mC), next-generation sequencing bisulfite pyrosequencing (NGS-BSP).

Article Snippet: Cells were treated with 5 μM decitabine (MedChemExpress) for demethylation experiments.

Techniques: Transfection, DNA Methylation Assay, CpG Methylation Assay, Knockdown, Enzyme-linked Immunosorbent Assay, Next-Generation Sequencing